EADV Congress 2022

September 7-10, 2022 | Milan & Online

We are pleased to share that our team will be attending EADV Congress 2022 in Milan this September. EADV Congress is an outstanding educational and learning experience for dermatologists and venereologists world-wide, and our team will be pleased to join it alongside our partner Legit.Health.

Alira Health and Legit.Health will be attending EADV Congress 2022 following the roll-out of the unique next generation technology solution for dermatology DCT, RWE and DTx. This joint solution is designed to automate the verification of inclusion criteria, automate participant monitoring and clinical endpoint acquisition and recruitment, and increase the diversity of participants. Learn more about the solution from the partnership announcement.

Our delegates
Andrea Mantovani

Andrea Mantovani

Vice President, Global Market Access & Pricing, Alira Health
Kumara Prasad Palanivel

Dr. Kumara Prasad Palanivel

Director, Digital Medical Strategy, Alira Health

Would you like to meet at EADV and learn more about our unique platform for dermatology DCT, RWE and DTx?

Related news

Publications September 20, 2023
UK HTA Approves TRANSLARNA (Ataluren) for Duchenne Muscular Dystrophy Citing Real-World Evidence
The NICE recommended routine funding for TRANSLARNA (ataluren) to treat Duchenne Muscular Dystrophy (DMD), based on RWE combined with feedback from patients, caregivers, and clinicians.
Real-World Evidence (RWE) RWE Decision Alert
Publications August 21, 2023
French HTA Approves ZOKINVY (Lonafarnib) Based on Evidence Package Including RWE
ZOKINVY (lonafarnib) has been approved for reimbursement in France, and real-world evidence (RWE) played a key role in this decision.
Real-World Evidence (RWE) RWE Decision Alert
Events July 25, 2023
ERS International Congress
We're excited to join the ERS International Congress in Milan to explore the latest advances in respiratory medicine and science.
Italy Real-World Evidence (RWE)
Events June 13, 2023
DSVR 2023
We are excited to share that we will be attending the DSVR 2023 - 15° Colloque Données de Santé en Vie Réelle.
France Real-World Evidence (RWE)
Blog May 4, 2023
How to Leverage Real-World Evidence to Achieve Orphan Drug Designation
Obtaining an orphan drug designation (ODD) is challenging and may require sponsors to leverage real-world evidence (RWE). Read the article to learn what ODD is, why it matters, and how RWE can help.
Orphan Drug Rare Disease Real-World Evidence (RWE)
Events April 26, 2023
MedTech Forum 2023
We are excited to share that we will be sponsoring and speaking at MedTech Forum 2023. The MedTech Forum is the largest health and medical technology industry conference in Europe and(...)
MedTech Real-World Evidence (RWE)
Blog April 17, 2023
Reimbursement of Rare Disease Drugs in Italy: Challenges and Hopes for the Future
When it comes to rare diseases, Italy has done a good job in bringing EMA-approved drugs, including orphan drugs, to the Italian market. But  multiple challenges exist, many of which(...)
Italy Market Access Pharma Rare Disease Real-World Evidence (RWE)
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.